Amended Current Report Filing (8-k/a)
April 06 2018 - 4:55PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange
Act of 1934
Date of Report (Date of earliest event reported):
April 6,
2018
(
February 16, 2018)
BIOSPECIFICS TECHNOLOGIES
CORP.
(Exact name of registrant as specified in its
charter)
Delaware
|
001-34236
|
11-3054851
|
(State or other jurisdiction
|
(Commission
|
(IRS Employer
|
of incorporation)
|
File Number)
|
Identification No.)
|
35 Wilbur Street
|
11563
|
Lynbrook, NY
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrants telephone number, including area code:
516.593.7000
N/A
(Former name or former address, if
changed since last report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a -12)
[ ] Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c)) Indicate by check
mark whether the registrant is an emerging growth company as defined in Rule 405
of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of
1934.
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act. [ ]
Introductory Comment
Throughout this Current Report on Form 8-K, the terms we,
us, our and Company refer to BioSpecifics Technologies Corp.
Item 8.01 Other Events
On February 16, 2018, the Company filed a Current Report on
Form 8-K (the Original Filing) providing the time and place of the Companys
2018 annual meeting of stockholders (the Annual Meeting) as well as the record
date for the Annual Meeting. This amendment to the Original Filing is being
filed for the purpose of correcting a scriveners error with regard to the
record date for the Annual Meeting, and should be read in conjunction with the
Original Filing. The record date for the Annual Meeting will be April 20, 2018.
All stockholders of record as of April 20, 2018 will be entitled to vote at the
Annual Meeting.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated: April 6, 2018
BioSpecifics Technologies Corp.
|
By:
|
/s/ Thomas L. Wegman
|
|
|
Name: Thomas L. Wegman
|
|
|
Title: President
|
3
BioSpecifics Technologies (NASDAQ:BSTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSpecifics Technologies (NASDAQ:BSTC)
Historical Stock Chart
From Apr 2023 to Apr 2024